Background. The expression of RET/PTC chimeras was demonstrated in 10% to (Surgery 2000;128:984-93.) 
MOLECULAR CHARACTERIZATION OF THE BROAD spectrum of neoplasms that arise from thyroid follicular epithelium is of increasing interest because of potential insights in human epithelial cell multistep carcinogenesis. Thyroid cancer of the papillary type is a well-differentiated tumor that accounts for 60% to 80% of all malignancies of the thyroid gland. The genetic background of papillary thyroid carcinoma (PTC) has been elucidated by identification of somatic rearrangements of the tyrosine kinase receptors RET and NTRK1, respectively. Both proto-oncogenes encode for transmembrane receptors for neural growth factors; RET was identified as 1 of the receptors for the glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN), whereas NTRK1 (synonymously designated TrkA) is 1 of the receptors for the nerve growth factor (NGF). 1 Receptor tyrosine kinase genes frequently are targets of oncogenic activation through chromosomal rearrangements fusing the tyrosine kinase (TK) domain to the amino terminus of different "activating" gene products, which all appear to be ubiquitously expressed. These replacements of the extracellular domains of the respective receptor in somatic cells lead to constitutive and ectopic expression of the resulting chimeric oncogenes, which causes an increased TK activity in tissues physiologically lacking the expression of RET and NTRK1, respectively. In papillary carcinoma of the thyroid gland, chimeric fusion proteins of the RET proto-oncogene (RET/PTC 1 to RET/PTC 7) have been reported in approximately 10% to 20% of sporadic tumors, whereas NTRK1-derived chimeric onco-
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Volume 128, Number 6 genes (TRK, TRK-T1,T-2, T-3) were detected less frequently (2%-10%). 2, 3 DNA rearrangements of both proto-oncogenes involve breakpoint cluster regions and are preferentially caused by intrachromosomal inversion of chromosome 10 for RET and chromosome 1 for NTRK1, respectively. The RET gene (in adults physiologically expressed preferentially in neuroendocrine tissues, such as parafollicular C cells of the thyroid gland) is mapped to 10q11.2 and organized in 21 exons. Because of alternative splicing of exon 20, the RET gene product exists in 2 isoforms, a short and a longer protein variant. The RETderived thyroid oncogene described first was generated by the fusion with H4 (RET/PTC 1), 4 and very recently, a variant recombination product has been described that encompasses 150 residues instead of 101 residues at the N-terminus of H4 (RET/PTC 1L, as in long). 5 Furthermore, RET is recombined with 5′ sequences of the regulatory subunit RIα of TK A localized on chromosome 17 (RET/PTC 2), 6 and ELE1 (RET/PTC 3, ∆3=3b=3r2, 3r3, 3a=4). [7] [8] [9] A recombination of RET with a gene from the golgin subfamily, GOLGA5 (RET/PTC 5) (identified in post-Chernobyl PTCs) has first been described as an "in vitro artifact" after gene transfer experiments with DNA obtained from a human sigmoid colon cancer (ret-II). 10 Very recently, 2 structurally related fusion transcripts with the activating 5′ portion provided by hTIF1 (RET/PTC 6) and RET-fused gene RFG7 (RET/PTC 7), respectively, and the formation of a RET-derived chimeric oncogene that involves an, as yet undefined, RETfused gene RFGX have been reported 11 (Fig 1) .
The NTRK1 gene, which is primarily expressed in neural tissues, is located on chromosome 1q21-22, and its coding sequences are interspersed within 17 exons; the 18 nucleotides mini-exon 9 undergoes alternative splicing. Since 1992, NTRK1 recombination products are commonly referred to as "TRK," the abbreviation for transforming receptor kinase with the addition of a "T" for thyroid oncogene and a consecutive number that indicates the chronologic succession of identification. 12 Oncogenic activation of NTRK1 is described by fusion with gene sequences that originate from TPM3, an isoform of non-muscle tropomyosin (TRK), 13 from the translated promotor region (TPR) gene (TRK-T1,-T2) 12, 14 and the socalled TRK-fused gene (TFG) mapped to chromosome 3 (TRK-T3). 15 The 78-bp chimeric exon generated by fusion of a coding sequence of TFG with exon 8 sequences of NTRK1 can be alternatively spliced, Schematic shows wild-type gene products of RET and NTRK1 TK receptors, respectively, and the known chimeric fusion products and their chromosomal location. Hybrid mRNAs are designated PTC1 to PTC7, TRK, T1 to T3, and 2h according to published nomenclature. Horizontal black bars indicate fusion points; vertical bars indicate the amplicon generated by duplex RT-PCR. In contrast with a predominant hot-spot fusion point in RET, several breakpoints are found in NTRK1, clustering in intronic sequences preceding the transmembrane domain. SP, signal peptide; CL, cadherin-like domain; CR, cysteine-rich domain; TM, transmembrane domain; IK, interkinase domain; DP, duplex RT-PCR; EC, extracellular domain; AE, alternative exon; JM, juxtamembrane domain.
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which produces 2 different TRK-T3 messenger RNA hybrids. 15 Breakpoints of the NTRK1-derived rearrangements that have been described so far cluster in the perimembrane region upstream of the TK domain of the receptor protein (Fig 1) . A fusion product of NTRK1 and the L7a ribosomal protein gene (TRK-2h) was observed after transfection of DNA from a human breast carcinoma cell line 16 and represents 1 of several in vitro-generated NTRK1 oncogenes. 17 There is general agreement that the thyroid gland is prone to radiation-induced strand breaks of double-stranded DNA. In childhood thyroid tumors from Belarus after the radioactive fallout in Chernobyl, RET/PTC 3 and RET/PTC 1 oncogenic rearrangements are frequently observed; RET/ PTC 5 to RET/PTC 7 and NTRK1 fusion gene products were identified as rare alterations. 11 Immunohistochemical evidence that, in 2 cases, the thyroid tumor arose from a follicular cell clone carrying the oncogenic RFG5/RET rearrangement 11 and the fact that RET-derived fusion products have also been found in thyroid adenomas 18 suggest that chromosomal rearrangements that involve the RET proto-oncogene are an early event in thyroid carcinogenesis. 19 The identification of chimeric recombination products that display oncogenic activity in PTCs soon implied the question of the prognostic potential of these molecular alterations. Based on the limited data available, some investigators have hypothesized that RET/PTC activation is preferentially associated with slow-growing tumors of low malignancy in elderly patients. 20, 21 In contrast, other studies found the activation of RET/PTC preferentially in PTCs of aggressive behavior 2 or in younger patients with lymphatic involvement. 22 To study the prognostic significance of rearrangements of the RET proto-oncogene and the NTRK1 gene, we analyzed tumor tissue of 119 patients with PTC who were treated in our tertiary care Endocrine Surgery referral center.
METHODS
Thyroid tissues. From 1988 to 1999, tumor tissue from 119 patients (82 female, 37 male) who underwent surgery for primary or recurrent PTC in our Endocrine Surgery referral center (selected by availability of material for analysis only) was intraoperatively harvested and immediately snap-frozen. The diagnosis of PTC was verified by histologic examination of the surgical specimens. Histopathologic confirmation of tumor presence was also performed on the frozen thyroid or lymph node tissue in areas directly adjacent to the tissue that was used for RNA extraction. According to the recommendations of our institute's Ethics Committee, informed consent was obtained from all patients, none of whom had a history of previous irradiation. The patient group consisted of Caucasians, predominantly originating from the northern part of Germany, which is an area of moderate iodine deficiency.
Chart review and statistics. Clinical data of surgical procedures performed, data of intraoperative findings, histopathologic data, and preoperative and postoperative status of the patients with PTC were documented and analyzed by means of an ACCESS-based software system designed by the authors (T. J. M and P. B. M). Cause-specific survival of patients with and without RET chimeras and/or NTRK1-derived oncogenic rearrangements was calculated by Kaplan-Meier analysis; significant differences were tested with either the chi-square test, the log rank test, or Student t test, using commercially available software (SPSS 8.0; SPSS Inc, Chicago, Ill).
Duplex reverse transcription-polymerase chain reaction (RT-PCR). Frozen tissue was crushed in liquid nitrogen, and total RNA extraction was performed by standard procedures according to the manufacturer's recommendations (TRIZOL; Life Technologies, Karlsruhe, Germany). If both primary tumor and lymph node metastases were available, RNA obtained from the metastases was preferred for RT-PCR analysis to minimize contamination with wild-type RET and NTRK1 mRNAs, which are expressed in parafollicular C cells and follicular cells of the thyroid, respectively. Two normal lymph nodes of patients who underwent resection for reasons other than cancer demonstrated only extremely weak expression of wild-type RET mRNA (representing ectopic transcription, presumably in lymphocytes), whereas no expression of rearranged RET hybrids was observed. For expression analysis by duplex RT-PCR, 0.5 µg RNA was reverse transcribed and subjected to PCR amplification with the use of a commercial kit (SuperScript One-Step RT-PCR System; Life Technologies). Fusion region-spanning oligonucleotides comprised of carboxy terminus sequences of RET and NTRK1, respectively, and 5′ sequences derived from the known activating recombinant genes and primers that amplify only the respective TK receptor were designed (Table  I) . With the use of a T3 thermocycler (Biometra, Goettingen, Germany), the reaction was performed in 25 µL volume containing 0.24 µmol/L upstream and downstream primers, 0.2 mmol/L of each dNTP, 1.4 mmol/L MgSO 4 , and 2 µL Qsolution (Qiagen, Hilden, Germany) for NTRK1 analysis, and 1.45 mmol/L MgSO 4 for RET analysis. After initial denaturation of the template at 70°C for 5 minutes, the temperature was lowered to 48°C for 30 minutes; reaction mix was then added, and RT-PCR was performed. Negative controls that omitted template and positive controls (RET, medullary thyroid carcinoma; NTRK1, normal thyroid tissue) were run with each PCR reaction. PCR products were electrophoresed on 6% Surgery December 2000 polyacrylamide gels and visualized under UV light after ethidium bromide staining.
In normal thyroid tissue, one would expect 2 amplicons for each of the 2 TK receptors: a lower band that represents short RET or NTRK1 fragments downstream of known breakpoints and an upper band that represents a long breakpointspanning wild-type fragment. Specimens that demonstrated either a single lower band (which indicated the loss of 5´ gene sequences) or a strong lower band accompanied by an only weak upper band were indicative for RET or NTRK1 rearrangements, respectively. In the case of RET analysis, a weak wild-type background observed in some samples originated either from C-cell contamination in thyroid specimens or from ectopic transcription of lymphocytes in lymph node metastases. Because of the ubiquitous expression of the TK receptor, wildtype expression of the NTRK1 mRNA may be found in all specimens. Samples that show overexpression of the short amplicon were suspicious for rearrangements and were therefore further analyzed by RT-PCR for the expression of the hybrid mRNA RET/PTC 1 to 7 (including the recently described variants RET/H4 [RET/PTC 1L] and RET/ELE1 [RET/PTC 4]) and for expression of TRK and TRK-T1 to T3, respectively (Table I ). The recombination product of TFG and NTRK1 undergoes alternative splicing of the chimeric exon 8; screening for the longer variant of TRK-T3 that contains a fusion point in NTRK1 exon 8 preceding the sense primer used for duplex RT-PCR was performed with specific oligonucleotides in all tumor samples (Table I ). For want of truly positive controls for the rare recombination products of RET and NTRK1, respectively, specific sense and antisense primers for each of the promotor sequences examined were used to control template quality and performance of the upstream oligo (Table I) .
Dye primer automated fluorescent sequencing of hybrid cDNAs. After reamplification and purification with affinity columns (QIAquick; Qiagen), fusion points of all chimeric PCR products that have been identified so far were characterized by direct automated sequencing (ALF Express II; Thermo Sequenase fluorescent labeled primer cycle sequencing kit with 7-deaza-dGTP; Amersham Pharmacia Biotech, Freiburg, Germany) with the use of Cy5-labeled upstream and downstream oligonucleotides that were described earlier (Fig 4) .
RESULTS
The extraction of total RNA in sufficient quality was successful in all 119 specimens available. RET expression analysis by duplex RT-PCR revealed the rearrangement of the proto-oncogene in 17 of 119 
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Volume 128, Number 6 samples (14.3%) that were analyzed (Fig 2) . The specific type of rearrangement was subsequently determined in 16 cases: 11 chimeras of 119 tumors (9.2%) were identified as RET/PTC 1; 1 chimera of 119 tumors (0.8%) was identified as RET/PTC 2; 3 chimeras of 119 tumors (2.5%) were identified as RET/PTC 3, and 1 chimera of 119 tumors (0.8%) was identified as the rare variant RET/PTC ∆3. Fusion oncogenes that represented RET/PTC 4 to RET/PTC 7 rearrangements were not identified.
Chimeric NTRK1 fusion products were found by duplex RT-PCR in 15 of 119 tumor samples (12.6%). Two chimeras (1.7%) were characterized as TRK rearrangement, 1 fusion oncogene (0.8%) as TRK-T3 rearrangement and another (0.8 %) as TRK-T2 rearrangement (Fig 3) .
Although the results of duplex RT-PCR strongly indicated the presence of NTRK1 recombinations in 11 tumors (9.2%) and the presence of a RET chimera in 1 PTC (0.8%), neither of the known fusion genes had been identified by sequence-specific primers in these samples. These results point to novel N-terminus fusion partners of RET and NTRK1 or indicate novel breakpoints either of the TK receptor involved or of 1 of the known promotor genes. Interestingly, 2 tumor samples showed rearrangements of both of the TK receptors that had been investigated. Results were obtained with the material of one and the same total RNA extraction of diminutive tissue pieces in each tumor, excluding the chance of having accidentally analyzed 2 neighboring tumors that arose from different follicular clones. The RET-derived chimeras of these tumors were identified as RET/PTC 1 and as the rare variant RET/PTC ∆3, respectively, whereas the NTRK1-derived hybrid mRNAs represent still uncharacterized rearrangements.
The mean age of all patients with PTC who were included in our study was 51 years; the mean age for patients who lacked recombinant oncogenes was 52 years, and the mean age of individuals who were designated rearrangement-positive (NTRK1 or RET) was 47 years (P = .407; Student t test; Table II ). This difference in age was more pronounced, but still not statistically significant (P = .121), if only patients with RET chimeras were compared with subjects who were rearrangement-negative. More than one half of all patients with PTC presented with extrathyroidal tumor extension at the time of diagnosis. Of this patient cohort, 15 of 63 tumors (24%) revealed rearranged mRNAs: 6 NTRK1 chimeras (9.5%) and 10 RET chimeras (15.8%). In a comparison of each 
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subgroup, 10 of 17 patients (59%) with RET recombination products had a stage pT4 tumor; individuals with involvement of NTRK1 fusion products or without detectable molecular alteration demonstrated extrathyroidal extension in 40% and 54% of cases, respectively (P = .62; chisquare test). No differences were observed regarding distant metastases, which occurred in 6% to 7% of all cases. Differences regarding locoregional lymph node metastases observed between patients with rearranged TK receptors and patients with rearrangement-negative PTC were statistically not significant: 64% of individuals (57/89) without detected chimeric oncogenes had stage N1 or N2 tumors; 88% of RET rearrangement-positive patients (P = .218) and 67% of subjects with rearrangement of the NTRK1 gene (P = .828) showed lymph node involvement. Taking into account that lymph node metastases are generally considered to be associated with worse outcome, a lower survival rate of our patients with RET/PTC chimeras would be expected. However, the contrary was true in our analysis; based on a mean follow-up of 5.7 years, the comparison of Kaplan-Meier estimates demonstrated that patients with RET rearrangements have a considerably better prognosis when compared with patients with NTRK1 rearrangements (P = .055; log rank test) or to patients without mutation (P = .242), despite the increased incidence of lymph node metastasis (Fig 5) . In contrast, patients with NTRK1-derived hybrid mRNAs seemed to have a worse prognosis when compared with patients without mutation (P = .109). Even if not statistically significant because of the small numbers, the fact that none of the RET rearrangement-positive patients died of tumor-related reasons (tumor stage, extent of distant metastasis, and follow-up period did not differ from the other groups) is remarkable; nevertheless, the average age of the respective patients was almost 10 years younger.
DISCUSSION
Somatic rearrangements of TK receptors that place the TK domain under the control of different promotor genes have been identified as the cause of malignant transformation in several neoplasms. In papillary carcinomas of the thyroid gland, nevertheless, the generation of chimeric TK oncogenes seems to be a distinct feature of the tumor, delimitating PTCs from other follicular epithelium-derived lesions. The fact that, up to now, at least 9 different RET-derived rearranged oncogenes and at least 4 different NTRK1-derived chimeric oncogenes were detected in human thyroid carcinoma of the papillary type (Fig 1) gives rise to speculation that for carcinogenesis generation of constitutive TK activity is relevant, regardless of the physiologic function of the genes that provide the promotor region. Chimeric fusion proteins sharing the TK domains of RET and NTRK1, respectively, have been shown to be associated with the malignant transformation in transfection studies, but little is known about the exact mechanisms involved. 23 All amino terminus fusion gene products juxtaposed to the TK domain of NTRK1 seem to represent ubiquitously expressed cytoplasmic proteins and therefore might be essential for cellular functions. Besides ubiquitous expression, a common feature shared by activating 5′ sequences from unrelated chromosomal loci fused to the RET proto-oncogene seems to be the presence of a coiledcoil domain, presumably enabling oligomerization of the hybrid gene product perpetuating a ligand-independent activation of the TK activity.
Based on the outlined considerations and supported by our finding of 1 RET rearrangement that involved a yet unidentified fusion gene and the finding of 11 yet uncharacterized NTRK1 fusion products in tumors of patients without a history of irradiation, it can be hypothesized that a considerable number of hybrid oncogenes associated with PTC still await identification. Therefore, a number of novel chimeric TK oncogenes (not detectable with the methodology used) might be presumed within the group of patients classified as rearrangement-negative in our statistical analysis, which prompts a careful interpretation of the survival test results. Although, in contrast with NTRK1 rearrangement-positive individuals, PTC patients who harbor RET-derived hybrid fusion genes demonstrated a tendentious, but statistically insignificant, improved survival, the difference to patients who are rearrangement-negative might become more evident with a growing number of recombinant oncogenes identified.
Analysis of chimeric recombination products is impaired by splice variants of hybrid mRNAs, which leads to varying product sizes, and by varying fusion points, especially within the NTRK1 gene, which may not be completely covered by a single duplex RT-PCR. In our study, primers for duplex RT-PCR analysis of the RET proto-oncogene were designed to surround the predominant hot spot for gene rearrangements. In the NTRK1 gene, in contrast, several intronic and exonic break points are observed (Fig 1) . In accordance with protocols of other investigators, 24 we initially used a duplex RT-PCR analyzing break points preceding NTRK1 exon 10; screening for TRK-T1 hybrid mRNAs with a fusion point in exon 11 was performed separately. However, the poor quality of the duplex RT-PCR and the fact that rearrangements with other 5′ unrelated sequences than the ones described so far might have been missed prompted us to design a duplex RT-PCR that included the fusion point of TRK-T1. As a result, the number of tumors that displayed chimeric sequences detected by duplex RT-PCR increased from 2 to 15 PTCs, including an alternatively spliced TFG/NTRK1 oncogene that harboring a yet undescribed break point (unpublished data). We refrained from a protocol that included simultaneous analysis of all TRK-T3 variants because the extension of the duplex RT-PCR amplification product by shifting the starter oligonucleotide upstream of NTRK1 exon 8 led to poor results.
PTCs that displayed oncogenic rearrangements of RET and NTRK1 were detected in 25% of the patients reported here and in up to 35% of PTCs of multicenter studies and 65% of post-Chernobyl tumors, respectively, assayed by other investigators. 1, 11, 25 However, studies on genotype-phenotype correlation reported ambiguous results. Although some authors observed RET/PTC expression preferentially in younger patients 22, 25 and in tumors with aggressive, locally invasive growth pattern, 2 others demonstrated the presence of the rearranged oncogenes in well-differentiated carcinomas of elderly patients without metastasis. 20, 21 Further support of the hypothesis that RET/PTC chimeras are associated with tumors of low malignancy is based on the assumed progression of PTCs to undifferentiated malignancies by means of the acquisition of additional p53 alterations. However, RET-derived fusion products have, to date, not been described in anaplastic carcinomas, although a high prevalence of TP53 point mutations is frequently observed in the latter neoplasms. 21 In our patient collective, too, the presence of chimeric RET oncogenes was associated with PTCs of low malignancy if tumor recurrence rate, extent of distant metastasis, and tumor-related survival were taken into account. Nevertheless, an analysis of cause-specific survival of patients with and without rearrangements of the TK receptors showed no significant difference in a univariate analysis using the log rank test, although a tendency toward a more malignant behavior of NTRK1 chimera-harboring tumors might be implicated. Interestingly, the 2 samples that demonstrated both RET and NTRK1 rearrangements are the only 2 of the 119 patients with distant lymph node metastases (N2) at time of diagnosis.
One half of the patients in our clinic demonstrated extrathyroidal extension of the tumor at the time of diagnosis, and a considerable number of patients showed infiltration of adjacent structures at the time of tissue collection. In 54% of cases, the patients underwent surgery for recurrent tumor growth with the use of aggressive resection procedures, including tracheal and esophageal reconstruction. 26 Therefore, our study cohort may include a bias because more advanced tumor stages are preferentially referred to our clinic. However, the incidence of chromosomal rearrangements of both TK receptors analyzed in patients with recurrent disease was not increased when compared with primary PTCs, which contradicts the assumption that these molecular alterations may be acquired during tumor progression.
The results of our 1-center study, comparing molecular tumor features with clinical outcome of 119 nonirradiated PTC patients (originating from the same geographic area) implicate the potential prognostic relevance of the gene rearrangements analyzed. Despite more advanced tumor stages, patients with RET/PTC chimeric oncogenes may benefit from aggressive surgical treatment includeing extended lymph node dissection, which was routinely performed in our patient cohort. Future identification of additional, yet undetected, molecular alterations in the presumably heterogeneous group of PTC characterized as rearrangement-negative at this time may lead to further support of our preliminary findings.
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